Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 398.65, up by 2.05 points or 0.52% from its previous closing of Rs. 396.60 on the BSE.

The scrip opened at Rs. 399.00 and has touched a high and low of Rs. 402.00 and Rs. 394.70 respectively. So far 176980 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 616.50 on 22-Oct-2018 and a 52 week low of Rs. 350.40 on 13-May-2019.

Last one week high and low of the scrip stood at Rs. 402.00 and Rs. 378.90 respectively. The current market cap of the company is Rs. 96105.36 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.91% and 12.71% respectively.

Sun Pharmaceutical Industries’ one of wholly owned subsidiaries has launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the US for oral use. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing - a problem that is estimated to affect approximately 30-35% of long-term care residents.

The US Food and Drug Administration (USFDA) had approved Drizalma Sprinkle on July 19, 2019.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.